Compare APRE & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APRE | AQMS |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 5.2M |
| IPO Year | 2019 | 2015 |
| Metric | APRE | AQMS |
|---|---|---|
| Price | $0.23 | $0.66 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.30 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 133.5K | 29.6K |
| Earning Date | 11-04-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $600.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.95 |
| 52 Week High | $1.49 | $8.31 |
| Indicator | APRE | AQMS |
|---|---|---|
| Relative Strength Index (RSI) | 26.17 | 22.41 |
| Support Level | N/A | N/A |
| Resistance Level | $0.81 | $2.98 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 8.91 | 0.00 |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Aqua Metals Inc is developing and seeking to commercialize proprietary recycling and refining technologies for the recovery of critical minerals and metals. Its patented and patent-pending AquaRefining process is an electro-hydrometallurgical method designed to recover high-purity materials from battery and other metal-bearing feedstocks using a closed-loop system powered by electricity. Its idea is to reduce CAPEX and OPEX costs, reduce emissions, hazardous waste, and reliance on conventional smelting and chemical-intensive refining processes. It has one operating segment: sustainable metals recycling. It focused on the development and commercialization of AquaRefining technology for the clean and efficient recovery of valuable metals from lead-acid and lithium-ion batteries.